Diagnosis and antibacterial treatment for community-acquired pneumonia in children during the COVID-19 pandemic
<p> <b>S.V. Zaitseva<sup>1,2</sup>, O.V. Zaitseva<sup>1</sup>, E.E. Lokshina<sup>1</sup></b> </p> <p> <b><sup>1</sup>A.I. Evdokimov Moscow University of Medicine & Dentistry, Moscow, Russian Federation</...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
LCC «Medicine-Inform»
2021-02-01
|
| Series: | РМЖ. Мать и дитя |
| Online Access: | http://wchjournal.com/upload/iblock/e56/e56f9e79798833973e53c3ac9581b4a9.pdf |
| Summary: | <p>
<b>S.V. Zaitseva<sup>1,2</sup>, O.V. Zaitseva<sup>1</sup>, E.E. Lokshina<sup>1</sup></b>
</p>
<p>
<b><sup>1</sup>A.I. Evdokimov Moscow University of Medicine & Dentistry, Moscow, Russian Federation</b>
</p>
<p>
<b><sup>2</sup>Federal Research Clinical Center for Children and Adolescents of the Federal Medical Biological Agency of Russia, Moscow, Russian Federation</b>
</p>
<p>
<i>During the COVID-19 pandemic, the reasonable use of antibiotics became an important issue of practical health care. This fact is accounted for by the heavy burden of COVID-19 on healthcare system, difficulties with interpreting respiratory disorders and verifying community-acquired pneumonia using instrumental and laboratory tests. Therefore, the risk of unnecessary prescription of antibiotics and, as a result, the prevalence of antibiotic resistance significantly increase. This paper addresses current ideas about the role of the most common causative agents of community-acquired pneumonia in children, the milestones of the diagnosis of community-acquired pneumonia, differential diagnosis of viral and bacterial pneumonia, the algorithms of the choice of basic antibacterial treatment in out-patient settings. The authors emphasize that only the use of limited antibiotic spectrum (i.e., amoxicillin, inhibitor-protected aminopenicillins), their rational dosing and course treatment recommended for community-acquired pneumonia will prevent the loss of antibacterial efficacy for infectious diseases.</i>
</p>
<p>
<i><b>Keywords</b>: community-acquired pneumonia, children, SARS-CoV-2, antibiotic therapy, antibiotic resistance, inhibitor-protected aminopenicillins.</i>
</p>
<p>
<i><b>For citation:</b> Zaitseva S.V., Zaitseva O.V., Lokshina E.E. Diagnosis and antibacterial treatment for community-acquired pneumonia in children during the COVID-19 pandemic. Russian Journal of Woman and Child Health. 2021;4(1):70–</i><i>76</i><i>. DOI: 10.32364/2618-8430-2021-4-1-70-</i><i>76</i><i>.</i>
</p>
<i><br>
</i><br> |
|---|---|
| ISSN: | 2618-8430 2686-7184 |